<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03797651</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-0782</org_study_id>
    <nct_id>NCT03797651</nct_id>
  </id_info>
  <brief_title>Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial</brief_title>
  <official_title>Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesized that ticagrelor monotherapy might be enough to prevent thromboembolic events
      without aspirin after PCI in patients with acute coronary syndrome(ACS). Moreover, ticagrelor
      monotherapy will reduce bleeding risk compared to DAPT with aspirin plus ticagrelor. We will
      also evaluate 1-year safety and efficacy of Orsiro stent for patient with acute coronary
      syndrome. After confirmation of enrollment, patients will be randomized to continue standard
      treatment (aspirin plus ticagrelor) for 1 year or to stop aspirin after discharge or less
      than 1 month after PCI (ticagrelor monotherapy). Randomization will be stratified according
      to 1) the presence of diabetes and 2) ST elevation myocardial infarction (MI). Baseline
      clinical and angiographic characteristics, laboratory findings will be assessed at the time
      of randomization. All patients will provide informed consent on their own initiative.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net clinical benefit</measure>
    <time_frame>1 year after procedure</time_frame>
    <description>A composite of all-cause death, MI, stent thrombosis, stroke, major bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each components of net clinical benefit</measure>
    <time_frame>1 year after procedure</time_frame>
    <description>All-cause death, MI, stent thrombosis, stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause or cardiovascular mortality</measure>
    <time_frame>1 year after procedure</time_frame>
    <description>All-cause or cardiovascular mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor bleeding</measure>
    <time_frame>1 year after procedure</time_frame>
    <description>Major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>1 year after procedure</time_frame>
    <description>A composite of cardiac death, MI, stent thrombosis, ischemia-driven target-vessel revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2850</enrollment>
  <condition>Coronary Artery Disease, Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Standard DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very-short DAPT within 1 month</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard DAPT</intervention_name>
    <description>Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.</description>
    <arm_group_label>Standard DAPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Very-short DAPT less than 1 month after PCI</intervention_name>
    <description>Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).</description>
    <arm_group_label>Very-short DAPT within 1 month</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥19 years old

          2. Patients who received new generation sirolimus-eluting (Orsiro® series) stent
             implantation for treating ACS, including acute MI and unstable angina

          3. Provision of informed consent

        Exclusion Criteria:

          1. Age&gt; 80 years

          2. Increased risk of bleeding, anemia, thrombocytopenia

          3. A need for oral anticoagulation therapy

          4. Pregnant women or women with potential childbearing

          5. Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Soo Jang, MD, PhD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>jangys1212@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 6, 2019</study_first_submitted>
  <study_first_submitted_qc>January 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

